Berberine reduces ischemia/reperfusion-induced myocardial apoptosis via activating AMPK and PI3K–Akt signaling in diabetic rats

Chen, Keke; Li, Guohua; Geng, Fenghao; Zhang, Zhao; Li, Jiani; Yang, Min; Dong, Ling; Gao, Feng

doi:10.1007/s10495-014-0977-0

Cited by 149 publications

(110 citation statements)

References 49 publications

Supporting

Mentioning

105

Contrasting

Order By: Relevance

“…16,30,31) BBR is a traditional herbal used to treat many gastrointestinal diseases worldwide. 2,3) Many studies have shown that BBR exhibits multiple pharmacological activities including antioxidant, anti-microbial, anti-tumor, and cholesterol-lowering effects. [4][5][6][7] Our previous studies found that BBR could reinforce the intestinal epithelial tight junction and reduce epithelial intestinal permeability in vitro and in vivo, which is important to maintain the intestinal mucosal barrier function.…”

Section: Discussionmentioning

confidence: 99%

Berberine Ameliorates Intestinal Mucosal Barrier Damage Induced by Peritoneal Air Exposure

Tan

Zhou

et al. 2015

Biol. Pharm. Bull.

View full text Add to dashboard Cite

Berberine, an isoquinoline alkaloid derived from many medicinal plants, has been extensively used to treat various gastrointestinal diseases. In the present study, we investigated whether berberine could ameliorate intestinal mucosal barrier damage induced by peritoneal air exposure for 3 h. Peritoneal air-exposure rats received 100, 150, and 200 mg/kg berberine orally via gavage four times before and after surgery. Blood and terminal ileum samples were collected 24 h after surgery. The serum D-lactate levels were determined using an enzyme-linked immunosorbent assay (ELISA) kit. Intestinal permeability was determined by measuring the intestinal clearance of fluorescein isothiocyanate (FITC)-dextran (FD4). Intestinal inflammation was assessed by measuring myeloperoxidase activity. Intestinal histopathology was also assessed. The results revealed that berberine decreased the serum D-lactate level, intestinal FD4 clearance, and myeloperoxidase activity. Edema and inflammation were reduced by berberine in the intestinal mucosa and submucosa, and the Chiu's scores, indices of intestinal mucosal injury, also decreased in the berberine-treated group. In addition, berberine exerted these protective effects in a dose-dependent manner, with a significant difference from the control group at doses of 150 and 200 mg/kg. The results suggest that berberine could ameliorate intestinal mucosal barrier damage induced by peritoneal air exposure, which is linked to its anti-inflammatory activity. Berberine may be a promising treatment for intestinal mucosal barrier damage in open abdominal surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Berberine Ameliorates Intestinal Mucosal Barrier Damage Induced by Peritoneal Air Exposure

Tan

Zhou

et al. 2015

Biol. Pharm. Bull.

View full text Add to dashboard Cite

show abstract

“…Berberine is an important alkaloid derived from Coptis chinensis Franch (Huang Lian). Previous studies [10][11] indicated that berberine had cardioprotective effects that included lowering lipids, reducing ischemia/reperfusion-induced myocardial apoptosis, and attenuating adverse left ventricular remodeling [12][13][14] . Our previous study in rats with acute myocardial infarction [15] showed that combined ligustrazine and berberine produced more effective inhibition of platelet activation and inflammatory reactions than did either agent separately.…”

Section: Introductionmentioning

confidence: 99%

Pretreatment with a combination of ligustrazine and berberine improves cardiac function in rats with coronary microembolization

Zhang

Guo

et al. 2016

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim:We have shown that a combination of ligustrazine and berberine produces more effective inhibition on platelet activation and inflammatory reactions in rat acute myocardial infarction compared with either agent alone. In this study we evaluated the beneficial effects of a combination of ligustrazine and berberine in a rat model of coronary microembolization (CME). Methods: SD rats were treated with ligustrazine, berberine, ligustrazine+berberine, or clopidogrel for 2 weeks. When the treatment completed, CME was induced by injection of sodium laurate into the left ventricular, while obstructing the ascending aorta. All rats were intubated for hemodynamic measurements. Blood samples were collected for biochemical analyses, flow cytometry, and ELISAs. Heart tissues were isolated for histopathology and subsequent protein analyses. Results: Pretreatment with the combination of ligustrazine (27 mg·kg -1 ·d -1 ) and berberine (90 mg·kg -1 ·d -1 ) significantly improved cardiac function, and decreased myocardial necrosis, inflammatory cell infiltration, microthrombosis and serum CK-MB levels in CME rats. In addition, this combination significantly decreased plasma ET-1 levels and von Willebrand factor, inhibited ADP-induced platelet activation, and reduced TNFα, IL-1β, ICAM-1 and RANTES levels in serum and heart tissues. The protective effects of this combination were more prominent than those of ligustrazine or berberine alone, but comparable to those of a positive control clopidogrel (6.75 mg·kg -1 ·d -1 ). Conclusion: The combination of ligustrazine and berberine significantly improved cardiac function in rat CME model via a mechanism involving antiplatelet and anti-inflammatory effects.

show abstract

“…Thus, we determined all three pairs of siRNA were capable of optimally protecting cardiomyocytes through the inhibition of IL28RA expression. PI3K/AKT was an important intracellular signal transduction pathway that regulates cell proliferation, differentiation, glucose metabolism and migration (18).…”

Section: Discussionmentioning

confidence: 99%

LncRNA260-specific siRNA targeting IL28RA gene inhibit cardiomyocytes hypoxic/reoxygenation injury

Gong

Yang

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Background:The interleukin 28 receptor alpha (IL28RA) gene was indicated to be associated with apoptosis.However, it was not clear whether long non-coding RNA 260 (lncRNA 260)-specific siRNA targeting IL28RA gene could inhibit hypoxic reoxygenation (H/R) cardiomyocytes injury or not. To explore the mechanisms underlying the protective effects of lncRNA260-specific siRNA-mediated inhibition of IL28RA from H/R injury in cardiomyocytes, the current research was performed.Methods: The primary neonatal rat cardiomyocytes were transfected with three different pairs of siRNA specific to lncRNA260 targeting IL28RA gene and then were undergone with the conditions simulating H/R injury.Results: All three groups of cardiomyocytes treated with lncRNA260-specific siRNA experienced significantly decreased levels of lactate dehydrogenase activity and apoptosis rate relative to the nontreatment and negative control groups (P<0.05), also expressed reduced levels of IL28RA, and increased levels of PI3KCG and Bcl-2/Bax (P<0.05). Conclusions:The lncRNA260-specific siRNA may reduce cardiomyocyte apoptosis associated with H/R injury by decreasing levels of the IL28RA gene product and thus activating the PI3K/AKT signaling pathway.Keywords: Interleukin 28 receptor alpha (IL28RA); siRNA; hypoxia and reoxygenation; phosphatidylinositol 3-kinase p110 gamma (PI3KCG);

show abstract

Berberine reduces ischemia/reperfusion-induced myocardial apoptosis via activating AMPK and PI3K–Akt signaling in diabetic rats

Cited by 149 publications

References 49 publications

Berberine Ameliorates Intestinal Mucosal Barrier Damage Induced by Peritoneal Air Exposure

Berberine Ameliorates Intestinal Mucosal Barrier Damage Induced by Peritoneal Air Exposure

Pretreatment with a combination of ligustrazine and berberine improves cardiac function in rats with coronary microembolization

LncRNA260-specific siRNA targeting IL28RA gene inhibit cardiomyocytes hypoxic/reoxygenation injury

Contact Info

Product

Resources

About